Show simple item record

dc.contributor.authorRichardson, Paul Gerard Guy
dc.contributor.authorLaubach, Jacob
dc.contributor.authorSchlossman, Robert Lawrence
dc.contributor.authorGhobrial, Irene
dc.contributor.authorMitsiades, Constantine S
dc.contributor.authorRosenblatt, Jacalyn Mara
dc.contributor.authorMahindra, Anuj
dc.contributor.authorRaje, Noopur
dc.contributor.authorMunshi, Nikhil C
dc.contributor.authorAnderson, Kenneth Carl
dc.date.accessioned2013-02-14T19:10:32Z
dc.date.issued2011
dc.identifier.citationRichardson, Paul G., Jacob P. Laubach, Robert L. Schlossman, Irene M. Ghobrial, Constantine S. Mitsiades, Jacalyn Rosenblatt, Anuj Mahindra, et al. 2011. The Medical Research Council myeloma IX trial: The impact on treatment paradigms. European Journal of Haematology 88(1): 1-7.en_US
dc.identifier.issn0902-4441en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10297258
dc.description.abstractOsteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino-bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non-intensive anti-myeloma treatment regimens in patients with newly diagnosed multiple myeloma. These results validate a large body of preclinical, translational and other clinical data suggesting anti-myeloma effects of amino-bisphosphonates. In addition, this trial also provided the first head-to-head evidence for superiority of one bisphosphonate over another (zoledronic acid vs. clodronate) for reducing skeletal morbidity in patients with multiple myeloma, as well as a prospective comparison of toxicities. Despite the use of non-bortezomib containing anti-myeloma treatment regimens in the MRC Myeloma IX trial, these results are encouraging and provide an impetus to continue to evaluate current treatment guidelines for myeloma-associated bone disease.en_US
dc.language.isoen_USen_US
dc.publisherBlackwell Publishing Ltden_US
dc.relation.isversionofdoi:10.1111/j.1600-0609.2011.01721.xen_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267050/pdf/en_US
dash.licenseLAA
dc.titleThe Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigmsen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalEuropean Journal of Haematologyen_US
dash.depositing.authorRichardson, Paul Gerard Guy
dc.date.available2013-02-14T19:10:32Z
dc.identifier.doi10.1111/j.1600-0609.2011.01721.x*
dash.authorsorderedfalse
dash.contributor.affiliatedSchlossman, Robert Lawrence
dash.contributor.affiliatedMahindra, Anuj
dash.contributor.affiliatedRosenblatt, Jacalyn
dash.contributor.affiliatedMitsiades, Constantine
dash.contributor.affiliatedLaubach, Jacob
dash.contributor.affiliatedRaje, Noopur
dash.contributor.affiliatedRichardson, Paul
dash.contributor.affiliatedMunshi, Nikhil
dash.contributor.affiliatedGhobrial, Irene
dash.contributor.affiliatedAnderson, Kenneth


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record